The FDA signaled a shift in its regulatory science agenda by planning to include aging and longevity among the topics highlighted in an updated Focus Areas of Regulatory Science (FARS) report. Speaking at the Aging Research & Drug Discovery Meeting at Harvard, FDA Chief Scientist Steven Kozlowski said the update is expected in early FY 2027. Kozlowski framed the agency’s goal as building pre-competitive, qualified endpoints that can support feasible clinical trial designs and improve accessibility for future development programs. Acting Chief of Staff Lowell M. Zeta also called longevity and healthspan an “important topic” for the FDA and HHS. The move matters for biotechs working on healthspan interventions and late-life indications because it points to an emerging emphasis on regulatory acceptance of shared endpoints—an area that has often slowed cross-program trial alignment and evidence generation.